David
Santamaría Velilla
Eli Lilly and Company
Indianapolis, EE. UU.Publikationen in Zusammenarbeit mit Forschern von Eli Lilly and Company (1)
2020
-
Tumor regression and resistance mechanisms upon CDK4 and RAF1 inactivation in KRAS/P53 mutant lung adenocarcinomas
Proceedings of the National Academy of Sciences of the United States of America, Vol. 117, Núm. 39, pp. 24415-24426